

New submissions

Bempedoic acid with ezetimibe	AMBER 2	Primary hypercholesterolaemia or mixed dyslipidaemia	As per NICE TA 694
Agomelatine	AMBER 2	Major depression in adults	Fourth-line option for the treatment of major depression in adults where other antidepressants have proven ineffective or poorly tolerated . Prescribing information sheet to follow
Nutrizym® 22	AMBER 2	Pancreatic Exocrine Insufficiency	Second line after Creon® For patients experiencing an allergic reaction or intolerance symptoms with Creon® .

News from the APC - updated/new documents on the APC website:

- [APC annual report](#)
- [Renal function calculations Statement \(New\)](#)
- [Antipsychotic prescribing guideline \(Update\)](#)
- [Clozapine information sheet \(Update\)](#)
- [Freestyle Libre prescribing criteria \(Update\)](#)
- [Prucalopride prescribing information sheet \(New\)](#)
- [DOACs in DVT and PE Guidance \(Update\)](#)
- [DOAC patient alert card \(Update\)](#)
- Antimicrobial guideline (Updates)
 - [Eczema](#)

Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) and Blood Pressure

SNRIs have been associated with dose-related, often sustained increases in both systolic and diastolic blood pressure. Use with caution in patients whose underlying conditions might be compromised by increases in blood pressure and heart rate. See the joint formulary entry [for venlafaxine and duloxetine](#) for more information.

Clozapine/olanzapine and smoking

Stopping smoking can increase clozapine and olanzapine blood levels. This applies to both cigarettes and cannabis. Be alert to smoking status and report any changes in smoking habit to the patient's specialist. Nicotine replacement therapy and E-cigarettes will NOT affect clozapine or olanzapine levels.

AMBER 3 traffic light classification - reminder of the definition



Primary care/ non specialist may initiate as per APC guideline.

The supporting prescribing guideline must have been agreed by the relevant secondary care trust D&TC and approved by the Nottinghamshire APC.

Horizon Scanning, Formulary amendments and traffic light changes

Formulary amendments:

- Elvanse Adult (Lisdexamphetamine) - Licensed in adults whereas Elvanse capsules aren't - prescribe by brand where possible so it's clear whether to supply Elvanse or Elvanse adult.
- Lecicarbon C - Removed temporary green classification which applied during bisacodyl shortages which are now rectified.
- Dulaglutide, semaglutide - to be prescribed by brand as per BNF advice (biological medications).
- Fentanyl patches - Clarified as **AMBER 2** for End of Life and for opioid naïve patients.
- Orlistat - Re-classified to **AMBER 3** restricted, weight management services only.
- Gliclazide and pioglitazone - reclassified as **AMBER 3** in line with other options for T2DM.
- Tiotropium, acridinium, umeclidinium inhaler and Salmeterol, olodaterol, formoterol Inhaler - Reclassified as **AMBER 3** for existing patients, **GREY** for new patients.
- Octasa suppositories - First line for new patients

Horizon scanning:

- ⇒ Beclometasone /formoterol/glycopyrronium inhaler (Trimbow®) - **GREY** no formal assessment for **asthma** indication

Current work in development

- Type 2 diabetes guideline (Update)
- Neuropathic pain guideline (Update)
- Amiodarone shared care protocol (New)
- Benzodiazepine and hypnotic guidance (update)
- Gastroprotection with antithrombotics (New)
- Hypertriglyceridaemia guidelines (Update)
- Unlicensed "Specials" – alternatives and options for prescribing (Update)
- Opioids for non-cancer pain (Update)
- Barrier preparation formulary (Update)

Title	Type	Anticipated publication
Clostridioides difficile infection: antimicrobial prescribing	Guideline	July 2021
Chronic kidney disease: assessment and management (update)	Guideline	July 2021
Type 1 diabetes in adults: diagnosis and management (update)	Guideline	July 2021
Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management	Guidance	August 2021
Esketamine for treatment-resistant depression	TA	TBC
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea	TA	TBC

The work of the NAPC is supported and managed by the interface team below. They can be contacted via nccg.nottsapc@nhs.net

Laura Catt, Prescribing Interface Advisor, NHS Nottingham and Nottinghamshire CCG

Lynne Kennell - Specialist interface and formulary pharmacist, Sherwood Forest Hospitals

Shary Walker - Specialist interface and formulary pharmacist, NUH

Karen Robinson, APC and Formulary Support Technician, NHS Nottingham and Nottinghamshire CCG

Jill Theobald, Specialist Interface Efficiencies Pharmacist, NHS Nottingham and Nottinghamshire CCG

Irina Varlan, Specialist Interface Efficiencies Pharmacist, NHS Nottingham and Nottinghamshire CCG

Hannah Godden, Specialist Mental Health Efficiencies Pharmacist, Nottinghamshire Healthcare Trust

Michalina Ogejo, Interface pharmacist, NHS Nottingham and Nottinghamshire CCG